Latest / Investor Exchange / Accrelist FY2026 Losses Narrow As Medical Aesthetics Revenue Rises

Transcript

Accrelist FY2026 Losses Narrow As Medical Aesthetics Revenue Rises · Investor Exchange

• 0:00
  Welcome to today's Deep Dive. We are jumping right in today because, honestly, the mission
• 0:13
  here is pretty clear-cut. For you listening, we're going to analyze the unaudited financial
• 0:19
  results of Acreolis Limited, and this is for the full year ending March 31st, 2026. We're
• 0:25
  looking at this strictly from an investor's perspective. No fluff, just the numbers and
• 0:29
  the strategy.
• 0:30
  Yeah, and it's a fascinating strategy to look at. We're basically breaking down how a company
• 0:35
  completely transformed its identity, shedding an industrial engineering arm to go all in
• 0:40
  on aesthetics and, strangely enough, the stock market.
• 0:43
  Exactly. I mean, we're talking about a corporate identity crisis that somehow miraculously
• 0:48
  managed to shrink an $8 million loss by over 80% in just one single year.
• 0:53
  That's wild. The top line numbers alone are just, well, they're definitely enough to make
• 0:57
  you do a double-take.
• 0:58
  For sure. Total revenue for continuing operations hit $15.6 million Singapore dollars. So that's
• 1:04
  up over 11% from the previous year.
• 1:06
  Double-digit revenue growth is always a good signal, right? But the real story here isn't
• 1:10
  just the top line. It's, you know, it's what happened to the bottom line.
• 1:13
  Right, the overall net loss.
• 1:15
  Exactly. The net loss shrank from nearly $7.9 million down to just $1.38 million. And, maybe
• 1:24
  even more importantly, gross profit margins jumped from 38% to nearly 47%.
• 1:30
  See, that margin leap is what immediately catches my eye. Jumping almost nine percentage
• 1:35
  points in a single year, especially right now in a pretty unpredictable economy, is
• 1:40
  huge.
• 1:41
  Oh, it's massive.
• 1:42
  Think of a leaky boat, right? The crew didn't just manage to patch the biggest holes in
• 1:46
  the hull, but they also somehow figured out how to catch a lot more fish at the exact
• 1:50
  same time.
• 1:51
  I like that analogy. Yeah.
• 1:52
  But, I mean, if you're an investor, you have to ask how. Usually, when a clinical company
• 1:56
  boosts revenue by 11%, you'd assume they spent a fortune on customer acquisition, like buying
• 2:01
  ads to get people through the door.
• 2:03
  You would think so, yeah. But if we dig into the report, their marketing and distribution
• 2:07
  expenses were actually slashed by over 44%.
• 2:11
  Wait, 44%? They cut marketing by almost half.
• 2:14
  Basically, yeah. They dropped from roughly $1.26 million down to just over $702,000.
• 2:21
  They completely gutted their external marketing budget.
• 2:26
  And they paired that with a really ruthless approach to administrative costs, like keeping
• 2:30
  manpower and training expenses super tightly controlled, even with all that revenue growth.
• 2:35
  Okay, so that perfectly sets up the next big question. To understand where that $15.6 million
• 2:42
  came from, we have to look at their core growth engine, right?
• 2:44
  Right. Their Aesthetic Medical Services division.
• 2:46
  Yeah, the clinics operating under the brand AM Aesthetics in Singapore and Malaysia. Plus,
• 2:51
  you know, they sell skincare products.
• 2:53
  That one single division generated $15.3 million of the total revenue, comparing the whole
• 2:59
  company.
• 3:00
  And it completely turned around its profitability, too. I mean, it flipped from a $1.1 million
• 3:04
  loss the previous year to a $1.4 million net profit this year.
• 3:08
  Which brings me right back to that marketing cut. Getting more people into clinic chairs
• 3:13
  usually costs money. If you cut your ad spend in a super competitive aesthetics market,
• 3:19
  foot traffic should just drop off a cliff.
• 3:21
  Normally, yeah, it would.
• 3:22
  So how did they actually drive this turnaround? You don't magically flip a million-dollar
• 3:27
  loss into a profit without ads, unless you're doing something really different.
• 3:32
  Well, you do it by changing what your existing staff actually does. The report specifically
• 3:37
  outlines that instead of paying external ad agencies, they engaged their own trained employees
• 3:43
  to push and promote treatments.
• 3:45
  Wait, like directly to the patients?
• 3:47
  Directly to the clients, yeah. They basically turned their clinic staff into this highly
• 3:51
  efficient direct-to-consumer sales team.
• 3:53
  Oh, wow. That is a really delicate balance to strike, though. Because, I mean, if you've
• 3:57
  ever been to a medical clinic, you want objective care. You don't want to feel like someone
• 4:01
  is selling you a used car while you're in the chair.
• 4:04
  Oh, absolutely. The psychology of turning medical staff into salespeople is really tricky.
• 4:09
  But when it works, it is incredibly lucrative.
• 4:13
  And the report notes they also trained these employees to manage the company's social
• 4:17
  media platforms in-house.
• 4:19
  So they aren't paying outside agencies for that either.
• 4:21
  Exactly. So their whole digital strategy shifted away from broad, expensive ads toward highly
• 4:27
  targeted special product promotions aimed straight at the customers they already have.
• 4:32
  Okay, that makes sense. They're maximizing the lifetime value of the patients already
• 4:36
  in the waiting room.
• 4:37
  Yeah.
• 4:38
  Because it's way cheaper to convince a satisfied patient to try a new dermal filler than it
• 4:43
  is to buy a new patient through an online ad.
• 4:46
  Right. And because they're keeping those customers and getting them to spend more per visit without
• 4:50
  those huge external marketing fees, that extra cash falls straight to the bottom line. That's
• 4:55
  your $1.4 million profit turnaround right there.
• 4:58
  Okay, so profitability on paper looks great. But if you're evaluating the stock, you always
• 5:03
  have to follow the actual cash.
• 5:05
  Always.
• 5:06
  And when we transitioned from the clinic's income statement to the reality of the company's
• 5:12
  bank accounts, there's a huge issue. They reported a negative working capital of $400,000.
• 5:18
  Yeah, that's definitely in there. But the board of directors stated they are confident
• 5:21
  they can operate as a going concern and meet their debt obligations over the next 12 months.
• 5:27
  I really have to push back on that from an investor's perspective. Negative working capital
• 5:33
  means your short-term liabilities exceed your short-term assets.
• 5:37
  Right.
• 5:38
  In plain English, if everyone called in their debts today, the company couldn't pay them.
• 5:43
  That is a major red flag. Why should anyone feel confident they can keep the lights on?
• 5:48
  I get why that looks terrifying, but you have to look at the specific mechanics of
• 5:52
  the aesthetic clinic business model. It's a cash-up-front business. When a customer
• 5:57
  comes in, they pay before they leave. There are basically zero credit terms.
• 6:01
  Oh, right. You just swipe your credit card at the front desk.
• 6:04
  Exactly. So the cash collection is immediate. They get the revenue well before their own
• 6:08
  invoices for supplies or rent are actually due.
• 6:11
  So the cash flow is strong because the money is literally just walking through the front
• 6:14
  door every day.
• 6:15
  Yeah, the daily HASS velocity is high. Plus, the company made a very specific choice not
• 6:20
  to pay a dividend to shareholders this year.
• 6:23
  Which is smart. If you're sitting on negative working capital, you need to conserve cash.
• 6:28
  Right. The report explicitly said it was to conserve cash for operations and, crucially,
• 6:34
  future investments.
• 6:35
  OK, but if the clinics generate so much immediate cash and they aren't paying a dividend, why
• 6:41
  is the working capital negative in the first place? Where did the money go?
• 6:45
  That's where we get to the strategic pivot. They are shedding their industrial weight
• 6:49
  and fundamentally changing their corporate identity.
• 6:52
  Yeah, moving away from complex engineering and doubling down on aesthetics and the stock
• 6:58
  market.
• 6:59
  Exactly. So first, they disposed of their mechanical engineering subsidiary, W.E. Total
• 7:04
  Engineering. That finished in March 2025.
• 7:06
  And they did that because of the challenging global landscape, right?
• 7:10
  Yeah, exactly. So all that revenue and those costs are just wiped off this year's books
• 7:14
  entirely.
• 7:15
  But selling off a struggling unit doesn't necessarily drain your working capital.
• 7:18
  No, it doesn't. What drained it were cash outflows for investments. Acreolus is pivoting
• 7:24
  hard into becoming an investment-focused holding company.
• 7:27
  OK, wait. So they took clinic profits and put them where?
• 7:30
  In the open stock market. In July and August of 2025, they spent hundreds of thousands
• 7:36
  of dollars buying millions of shares in a listed company called McLean Technologies.
• 7:41
  Wait, really? Just buying open market equities? That's an intense pivot. So Acreolus is undergoing
• 7:47
  this massive shift, ditching engineering to essentially run a profitable clinic to fund
• 7:53
  a stock portfolio.
• 7:54
  I mean, that's what the negative working capital reflects. The cash outflow went into
• 7:58
  those shares. But management highlights that McLean is a profitable company, and those
• 8:03
  shares are currently trading above Acreolus' acquisition price.
• 8:06
  Still, as an investor, you have to ask yourself, are you buying into a clinical aesthetics
• 8:10
  brand or are you buying into a corporate holding company day trading tech stocks?
• 8:15
  It's a fair question. It's a really aggressive strategy.
• 8:19
  Because if consumer spending drops and clinic foot traffic slows down, at the same time
• 8:24
  McLean stock dips, that negative working capital suddenly becomes a massive liquidity crisis.
• 8:29
  Yeah, which is why they really need the aesthetic side to not just stay stable, but to grow.
• 8:34
  And they do have a plan for that.
• 8:36
  Right. The future expectations.
• 8:37
  Right.
• 8:38
  So with rising demand for aesthetics, competition is getting stiffer everywhere. How are they
• 8:42
  planning to stand out and capture new markets?
• 8:44
  Well, they're looking at some big industry tailwinds, an aging population, rising overall
• 8:49
  affluence in the region. But specifically, they're targeting the growing acceptance
• 8:53
  of these procedures among younger customers and men.
• 8:56
  Oh, targeting men is huge. If you can normalize clinical skincare for men the way it is for
• 9:02
  women, you basically double your total addressable market overnight.
• 9:06
  Exactly. And to do that, they have two main growth strategies. First, they are launching
• 9:11
  original design manufacturer, or ODM, skincare products.
• 9:15
  Their AM skincare line.
• 9:16
  Right. And they are designing these directly with South Korean dermatologists.
• 9:20
  That is a great hook. South Korean skincare has incredible global brand equity.
• 9:26
  Oh, for sure. And they aren't just selling it in the clinics. They're planning to open
• 9:30
  a dedicated physical retail shop just for the clinical skincare products.
• 9:35
  That makes a lot of sense. You don't need to book a medical consultation just to buy
• 9:38
  a serum. It's pure retail top line growth.
• 9:42
  Exactly.
• 9:43
  But the second strategy is the one that really stood out to me. They aren't just staying
• 9:47
  in Singapore and Malaysia. They actually incorporated a new company in Hainan, China.
• 9:52
  Yeah, that's their international expansion play, tapping into revenue streams way beyond
• 9:57
  their current footprint.
• 9:58
  I mean, Hainan is being pushed as this massive medical tourism hub, which sounds great. But
• 10:04
  expanding a medical brand into China is incredibly complex.
• 10:07
  It's notoriously difficult.
• 10:09
  The regulations, the local competition, the definition of a high-risk, high-reward move.
• 10:14
  Yeah. If they nail it, the revenue potential is astronomical. But if they don't, it could
• 10:18
  be a massive drain on those cash reserves they just spent a year trying to build up.
• 10:22
  Right. So let's just recap the key takeaways here for the listener. Acreolis is definitely
• 10:28
  a leaner company now. They successfully shed their industrial baggage and pivoted into
• 10:32
  a cash-rich, highly profitable aesthetics business.
• 10:36
  Right. They shrunk their net losses by over 80 percent, boosted margins to 47 percent,
• 10:42
  and essentially internalized their marketing to drive massive clinic profits.
• 10:48
  But on the flip side, they're navigating a really tight spot with negative working capital,
• 10:53
  relying entirely on that daily cash upfront model to stay afloat, all while investing
• 10:58
  hundreds of thousands in open market tech stocks.
• 11:01
  It's definitely a balancing act. They've replaced the old risks of industrial engineering
• 11:05
  with the new risks of the stock market and hyper-competitive retail expansion.
• 11:09
  Which leaves you with a final thought to mull over as you analyze this company. Will their
• 11:13
  incredibly ambitious expansion into the massive yet complicated Chinese market be the exact
• 11:19
  catalyst that finally erases the group's overall losses? Or will it just drain the vital cash
• 11:25
  reserves they've worked so hard to protect?
• 11:26
  I guess we'll have to see what the next financial year brings.
• 11:29
  This content is intended to serve strictly and only as an informational, independent,
• 11:34
  objective summary of recent events, and should in no way be interpreted, construed, or relied
• 11:39
  upon by any party as inside information or financial advice.